您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > MCC950 sodium
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
MCC950 sodium
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
MCC950 sodium图片
CAS NO:256373-96-3
包装与价格：
包装价格(元)
10mg电议
50mg电议
200mg电议

产品介绍

化学性质

StorageStore at -20°C
M.Wt426.46
Cas No.256373-96-3
FormulaC20H23N2NaO5S
SynonymsCRID3 sodium salt
Solubility≥124 mg/mL in H2O; ≥21.45 mg/mL in DMSO; ≥43 mg/mL in EtOH
Chemical Namesodium ((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)((4-(2-hydroxypropan-2-yl)furan-2-yl)sulfonyl)amide
Canonical SMILESO=S([N-]C(NC1=C2CCCC2=CC3=C1CCC3)=O)(C4=CC(C(O)(C)C)=CO4)=O.[Na+]
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

MCC950 sodium salt is a potent, selective inhibitor of NOD-like receptor family protein 3 (NLRP3) with IC50 value of 7.5 nM in bone marrow derived macrophages (BMDMs) [1].

MCC950 effectively and selectively inhibits NLRP3 which is involved in various biological processes including autoinflammatory and autoimmune diseases. MCC950 is thus a potential therapeutic for NLRP3-associated syndromes, and a tool for the further study of the NLRP3 inflammasome in human health and disease [1].

In BMDM and human monocyte derived macrophage (HMDM) cells, MCC950 specifically inhibited canonical and noncanonical NLRP3 activation at IC50 of 7.5 nM and 8.1 nM, respectively, without affecting absent in melanoma 2 (AIM2), NOD-like receptor family CARD domain containing protein 4 (NLRC4) or NLRP1 inflammasomes [1].

In mice intraperitoneally injected with lipopolysaccharides (LPS), pre-treatment with MCC950 (50 mg/kg, i.p., 1 h before LPS injection) reduced serum concentrations of interleukin-1β (IL-1β) and IL-6 while it did not considerably decrease the amount of tumor necrosis factor-α (TNF-α). MCC950 attenuated the severity of experimental autoimmune encephalomyelitis [1].

Reference:

[1]. Coll R C, Robertson A A, Chae J J. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 2015, 21(3): 248-255.

试验操作

Cell experiment:[1]

Cell lines

Bone marrow derived macrophages (BMDMs), human monocyte–derived macrophages (HMDMs), and human peripheral blood mononuclear cells (PBMCs)

Reaction Conditions

0.001 ~ 10 μM MCC950 sodium for 30 min incubation

Applications

Treating cells with nanomolar concentrations of MCC950 sodium dose-dependently inhibited the release of interleukin-1β (IL-1β) in BMDMs, HMDMs, and PBMCs. LPS-dependent tumor necrosis factor-α (TNF-α) secretion was not impaired by MCC950 sodium, which demonstrated that the inhibition effect of MCC950 sodium on IL-1β secretion was specific.

Animal experiment:[1]

Animal models

C57BL/6 mice

Dosage form

10 and 50 mg/kg

Injected intraperitoneally (i.p.)

Applications

In mice intraperitoneally injected with lipopolysaccharides (LPS), pre-treatment with MCC950 sodium (50 mg/kg, i.p., 1 h before LPS injection) reduced serum concentrations of IL-1β and IL-6 while it did not considerably decrease the amount of TNF-α. Furthermore, MCC950 sodium (10 mg/kg, i.p.) attenuated the severity of experimental autoimmune encephalomyelitis, a disease model of multiple sclerosis.

Note

The technical data provided above is for reference only.

References:

1. Coll RC, Robertson AA, Chae JJ. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nature Medicine, 2015, 21(3): 248-255.